BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 27802546)

  • 1. Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients With Recessive Dystrophic Epidermolysis Bullosa.
    Siprashvili Z; Nguyen NT; Gorell ES; Loutit K; Khuu P; Furukawa LK; Lorenz HP; Leung TH; Keene DR; Rieger KE; Khavari P; Lane AT; Tang JY; Marinkovich MP
    JAMA; 2016 Nov; 316(17):1808-1817. PubMed ID: 27802546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa.
    So JY; Nazaroff J; Iwummadu CV; Harris N; Gorell ES; Fulchand S; Bailey I; McCarthy D; Siprashvili Z; Marinkovich MP; Tang JY; Chiou AS
    Orphanet J Rare Dis; 2022 Oct; 17(1):377. PubMed ID: 36253825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa.
    Eichstadt S; Barriga M; Ponakala A; Teng C; Nguyen NT; Siprashvili Z; Nazaroff J; Gorell ES; Chiou AS; Taylor L; Khuu P; Keene DR; Rieger K; Khosla RK; Furukawa LK; Lorenz HP; Marinkovich MP; Tang JY
    JCI Insight; 2019 Oct; 4(19):. PubMed ID: 31578311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients.
    Woodley DT; Cogan J; Hou Y; Lyu C; Marinkovich MP; Keene D; Chen M
    J Clin Invest; 2017 Aug; 127(8):3028-3038. PubMed ID: 28691931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene-Corrected Fibroblast Therapy for Recessive Dystrophic Epidermolysis Bullosa using a Self-Inactivating COL7A1 Retroviral Vector.
    Jacków J; Titeux M; Portier S; Charbonnier S; Ganier C; Gaucher S; Hovnanian A
    J Invest Dermatol; 2016 Jul; 136(7):1346-1354. PubMed ID: 26994967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highly Efficient Ex Vivo Correction of COL7A1 through Ribonucleoprotein-Based CRISPR/Cas9 and Homology-Directed Repair to Treat Recessive Dystrophic Epidermolysis Bullosa.
    Berthault C; Gaucher S; Gouin O; Schmitt A; Chen M; Woodley D; Titeux M; Hovnanian A; Izmiryan A
    J Invest Dermatol; 2024 Jun; 144(6):1322-1333.e13. PubMed ID: 38043638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Collagen VII Expression Is Required in Both Keratinocytes and Fibroblasts for Anchoring Fibril Formation in Bilayer Engineered Skin Substitutes.
    Supp DM; Hahn JM; Combs KA; McFarland KL; Schwentker A; Boissy RE; Boyce ST; Powell HM; Lucky AW
    Cell Transplant; 2019; 28(9-10):1242-1256. PubMed ID: 31271052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa.
    Chen M; Kasahara N; Keene DR; Chan L; Hoeffler WK; Finlay D; Barcova M; Cannon PM; Mazurek C; Woodley DT
    Nat Genet; 2002 Dec; 32(4):670-5. PubMed ID: 12426566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction of Recessive Dystrophic Epidermolysis Bullosa by Transposon-Mediated Integration of COL7A1 in Transplantable Patient-Derived Primary Keratinocytes.
    Latella MC; Cocchiarella F; De Rosa L; Turchiano G; Gonçalves MAFV; Larcher F; De Luca M; Recchia A
    J Invest Dermatol; 2017 Apr; 137(4):836-844. PubMed ID: 28027893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SIN retroviral vectors expressing COL7A1 under human promoters for ex vivo gene therapy of recessive dystrophic epidermolysis bullosa.
    Titeux M; Pendaries V; Zanta-Boussif MA; Décha A; Pironon N; Tonasso L; Mejia JE; Brice A; Danos O; Hovnanian A
    Mol Ther; 2010 Aug; 18(8):1509-18. PubMed ID: 20485266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human Mesenchymal Stromal Cells Engineered to Express Collagen VII Can Restore Anchoring Fibrils in Recessive Dystrophic Epidermolysis Bullosa Skin Graft Chimeras.
    Petrova A; Georgiadis C; Fleck RA; Allison L; McGrath JA; Dazzi F; Di WL; Qasim W
    J Invest Dermatol; 2020 Jan; 140(1):121-131.e6. PubMed ID: 31326396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of patients with recessive dystrophic epidermolysis bullosa in the Netherlands: expansion of the mutation database and unusual phenotype-genotype correlations.
    van den Akker PC; van Essen AJ; Kraak MM; Meijer R; Nijenhuis M; Meijer G; Hofstra RM; Pas HH; Scheffer H; Jonkman MF
    J Dermatol Sci; 2009 Oct; 56(1):9-18. PubMed ID: 19665875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction of skin equivalents for gene therapy of recessive dystrophic epidermolysis bullosa.
    Gache Y; Baldeschi C; Del Rio M; Gagnoux-Palacios L; Larcher F; Lacour JP; Meneguzzi G
    Hum Gene Ther; 2004 Oct; 15(10):921-33. PubMed ID: 15585108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional correction of type VII collagen expression in dystrophic epidermolysis bullosa.
    Murauer EM; Gache Y; Gratz IK; Klausegger A; Muss W; Gruber C; Meneguzzi G; Hintner H; Bauer JW
    J Invest Dermatol; 2011 Jan; 131(1):74-83. PubMed ID: 20720561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa.
    Venugopal SS; Yan W; Frew JW; Cohn HI; Rhodes LM; Tran K; Melbourne W; Nelson JA; Sturm M; Fogarty J; Marinkovich MP; Igawa S; Ishida-Yamamoto A; Murrell DF
    J Am Acad Dermatol; 2013 Dec; 69(6):898-908.e7. PubMed ID: 24075228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa.
    Wong T; Gammon L; Liu L; Mellerio JE; Dopping-Hepenstal PJ; Pacy J; Elia G; Jeffery R; Leigh IM; Navsaria H; McGrath JA
    J Invest Dermatol; 2008 Sep; 128(9):2179-89. PubMed ID: 18385758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone.
    Woodley DT; Krueger GG; Jorgensen CM; Fairley JA; Atha T; Huang Y; Chan L; Keene DR; Chen M
    J Invest Dermatol; 2003 Nov; 121(5):1021-8. PubMed ID: 14708601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial.
    Gurevich I; Agarwal P; Zhang P; Dolorito JA; Oliver S; Liu H; Reitze N; Sarma N; Bagci IS; Sridhar K; Kakarla V; Yenamandra VK; O'Malley M; Prisco M; Tufa SF; Keene DR; South AP; Krishnan SM; Marinkovich MP
    Nat Med; 2022 Apr; 28(4):780-788. PubMed ID: 35347281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblasts show more potential as target cells than keratinocytes in COL7A1 gene therapy of dystrophic epidermolysis bullosa.
    Goto M; Sawamura D; Ito K; Abe M; Nishie W; Sakai K; Shibaki A; Akiyama M; Shimizu H
    J Invest Dermatol; 2006 Apr; 126(4):766-72. PubMed ID: 16439972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of collagen VII sequence variants found in Australasian patients with dystrophic epidermolysis bullosa reveals nine novel COL7A1 variants.
    Dang N; Klingberg S; Marr P; Murrell DF
    J Dermatol Sci; 2007 Jun; 46(3):169-78. PubMed ID: 17425959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.